Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedUpdated page to v3.2.0 with a new government-operating-status notice; removed the resource for Differentiated thyroid carcinoma from the Genetic and Rare Diseases Information Center.SummaryDifference3%
- Check23 days agoChange DetectedThe page has been updated to include new dates, a EU Trial CTIS number, revision version, and update indicators, while several historical safety-related sections and older update references were removed. Overall, the changes mainly update metadata and identifiers rather than core content.SummaryDifference1%
- Check37 days agoChange Detected- Revision updated from v3.0.1 to v3.0.2; removed the Back to Top link.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check51 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous specific locations and facility names across various countries, as well as the introduction of new medical terms related to drug safety and thyroid cancer. Notably, the previous version's references to certain locations and terms have been removed.SummaryDifference21%
- Check66 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.